Sequential Gas Delivery

PreclinicalSmall molecule

Sequential Gas Delivery is one of 7 small molecule programs targeting Orthostatic Hypotension. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Orthostatic HypotensionActive, not recruiting

Orthostatic HypotensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Orthostatic Hypotension

#DrugCompanyPhaseTrials

Northera

Lundbeck

Approved

10 2

Proamatine

Takeda

Approved

7 3

Corlanor

Amgen

Approved

—4

Inderal

WWyeth-Lederle Vaccines

Mestinon

1 6

Midodrine or Atomoxetine Pill

VVanderbilt University Medical Center

Preclinical

—7

Sequential Gas Delivery

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Orthostatic Hypotension

NCT05295810

Clinical

Trials by Indication[1]

Orthostatic Hypotension1 trial

Hypercapnia in Orthostatic Hypotension

Recruiting·UUniversity of Calgary·N/A·NCT05295810·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sequential Gas Delivery. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sequential Gas Delivery compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sequential Gas Delivery. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Calgary

Sequential Gas Delivery

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Orthostatic Hypotension1 trial

References

Drug Info

Quick Facts

Related News